The spectrum of giant cell arteritis through a rheumatology lens
Open Access
- 19 June 2024
- journal article
- review article
- Published by Springer Nature in Eye
- Vol. 38 (12) , 2437-2447
Abstract
Treatment of giant cell arteritis (GCA) aims initially to prevent acute visual loss, and subsequently to optimise long-term quality of life. Initial prevention of acute visual loss in GCA is well-standardised with high-dose glucocorticoid therapy but in the longer term optimising quality of life requires tailoring of treatment to the individual. The licensing of the IL-6 receptor inhibitor tocilizumab combined with advances in vascular imaging have resulted in many changes to diagnostic and therapeutic practice. Firstly, GCA is a systemic disease that may involve multiple vascular territories and present in diverse ways. Broadening of the “spectrum” of what is called GCA has been crystallised in the 2022 GCA classification criteria. Secondly, the vascular inflammation of GCA frequently co-exists with the extracapsular musculoskeletal inflammation of the related disease, polymyalgia rheumatica (PMR). Thirdly, GCA care must often be delivered across multiple specialities and healthcare organisations requiring effective interprofessional communication. Fourthly, both GCA and PMR may follow a chronic or multiphasic disease course; long-term management must be tailored to the individual patient’s needs. In this article we focus on some areas of current rheumatology practice that ophthalmologists need to be aware of, including comprehensive assessment of extra-ocular symptoms, physical signs and laboratory markers; advanced imaging techniques; and implications for multi-speciality collaboration.Keywords
This publication has 109 references indexed in Scilit:
- The influence of sectional interval on the reliability of temporal arterial biopsies in polymyalgia rheumaticaClinical Rheumatology, 1995
- Colour doppler sonography to diagnose temporal arteritisThe Lancet, 1995
- Visual Morbidity in Giant Cell ArteritisOphthalmology, 1994
- Tissue Cytokine Patterns in Patients with Polymyalgia Rheumatica and Giant Cell ArteritisAnnals of Internal Medicine, 1994
- Illustrated histopathologic classification criteria for selected vasculitis syndromesArthritis & Rheumatism, 1990
- Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study.Annals of the Rheumatic Diseases, 1986
- Acute Phase Reactants in the Initial Phase of Giant Cell ArteritisActa Medica Scandinavica, 1986
- Treatment of polymyalgia rheumaticaArthritis & Rheumatism, 1982
- Temporal arteritis in a large necropsy series.Annals of the Rheumatic Diseases, 1971
- “Polymyalgia arteritica”. Further clinical and histopathological studies with a report of six autopsy cases.Annals of the Rheumatic Diseases, 1968